治疗突变型肺癌的药物。
Agents to treat mutant lung cancer.
作者信息
Alvarez Jean G Bustamante, Otterson Gregory A
机构信息
Division of Medical Oncology, Department of Internal Medicine, The James Cancer Center and Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
出版信息
Drugs Context. 2019 Mar 13;8:212566. doi: 10.7573/dic.212566. eCollection 2019.
Abstract
mutations are seen in up to 3.5-4% of the non-small cell lung cancer (NSCLC) patients. mutations account for 50% of these cases, and the remaining mutations are non-V600E. The biologic behavior of -mutated lung tumors tends to be more aggressive and resistant to chemotherapy, but responses to tyrosine kinase inhibitors such as BRAF inhibitors with or without MEK inhibitors have provided another effective tool to attain better response rates when compared to cytotoxic chemotherapy. New strategies such as immunotherapy are becoming as well another option to treat in the second-line setting patients with -mutated NSCLC.
摘要
在高达3.5%-4%的非小细胞肺癌（NSCLC）患者中可发现突变。其中，V600E突变占这些病例的50%，其余突变是非V600E突变。BRAF突变的肺肿瘤的生物学行为往往更具侵袭性且对化疗耐药，但与细胞毒性化疗相比，使用酪氨酸激酶抑制剂（如BRAF抑制剂，联合或不联合MEK抑制剂）可提供另一种有效手段以获得更高的缓解率。免疫疗法等新策略也正成为二线治疗BRAF突变NSCLC患者的另一种选择。
相似文献
1
Agents to treat mutant lung cancer.
Drugs Context. 2019 Mar 13;8:212566. doi: 10.7573/dic.212566. eCollection 2019.
2
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
PLoS One. 2015 Feb 23;10(2):e0118210. doi: 10.1371/journal.pone.0118210. eCollection 2015.
3
FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Mutations.
Oncologist. 2018 Jun;23(6):740-745. doi: 10.1634/theoncologist.2017-0642. Epub 2018 Feb 7.
4
Successful re-challenge of dabrafenib-trametinib combination therapy in advanced -mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report.
Ann Transl Med. 2022 Sep;10(18):1029. doi: 10.21037/atm-22-3887.
5
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
6
Adverse Event Management in Patients with V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.
Oncologist. 2019 Jul;24(7):963-972. doi: 10.1634/theoncologist.2018-0296. Epub 2018 Dec 31.
7
Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E-mutated lung adenocarcinoma.
Respirol Case Rep. 2021 Aug 30;9(10):e0841. doi: 10.1002/rcr2.841. eCollection 2021 Oct.
8
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Sci Transl Med. 2015 Mar 18;7(279):279ra41. doi: 10.1126/scitranslmed.aaa4691.
9
Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in V600E-mutated lung cancer.
Transl Lung Cancer Res. 2021 Sep;10(9):3737-3744. doi: 10.21037/tlcr-21-415.
10
Clinical Characteristics, Co-Mutations, and Treatment Outcomes in Advanced Non-Small-Cell Lung Cancer Patients With the BRAF-V600E Mutation.
Front Oncol. 2022 Jun 22;12:911303. doi: 10.3389/fonc.2022.911303. eCollection 2022.
引用本文的文献
1
mutated lung adenocarcinoma with thyroid metastasis as the initial manifestation: a case report.
Front Oncol. 2025 Feb 6;15:1468233. doi: 10.3389/fonc.2025.1468233. eCollection 2025.
2
Identification of a central network hub of key prognostic genes based on correlation between transcriptomics and survival in patients with metastatic solid tumors.
Ther Adv Med Oncol. 2024 Oct 17;16:17588359241289200. doi: 10.1177/17588359241289200. eCollection 2024.
3
Therapeutic Opportunities for Biomarkers in Metastatic Spine Tumors.
Cancers (Basel). 2024 Sep 14;16(18):3152. doi: 10.3390/cancers16183152.
4
Differential contribution for ERK1 and ERK2 kinases in BRAF-triggered phenotypes in adult mouse models.
Cell Death Differ. 2024 Jun;31(6):804-819. doi: 10.1038/s41418-024-01300-x. Epub 2024 May 2.
5
Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine.
Iran J Basic Med Sci. 2024;27(2):122-133. doi: 10.22038/IJBMS.2023.72407.15749.
6
The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer Cells.
Cancers (Basel). 2023 Dec 12;15(24):5805. doi: 10.3390/cancers15245805.
7
Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022.
Cancer Innov. 2023 Mar 1;2(1):25-35. doi: 10.1002/cai2.56. eCollection 2023 Feb.
8
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer.
Pharmaceutics. 2023 Apr 16;15(4):1252. doi: 10.3390/pharmaceutics15041252.
9
Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer.
J Pers Med. 2023 Jan 17;13(2):167. doi: 10.3390/jpm13020167.
10
In vitro and in vivo analyses on anti-NSCLC activity of apatinib: rediscovery of a new drug target V600E mutation.
Cancer Cell Int. 2023 Feb 9;23(1):21. doi: 10.1186/s12935-022-02723-7.
本文引用的文献
1
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.
Clin Cancer Res. 2019 Jan 1;25(1):158-165. doi: 10.1158/1078-0432.CCR-18-2062. Epub 2018 Sep 17.
2
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.
Cancer Treat Rev. 2018 May;66:82-94. doi: 10.1016/j.ctrv.2018.04.006. Epub 2018 Apr 24.
3
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors.
J Thorac Oncol. 2018 Aug;13(8):1128-1137. doi: 10.1016/j.jtho.2018.04.024. Epub 2018 Apr 30.
4
Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.
Exp Hematol Oncol. 2017 Nov 6;6:29. doi: 10.1186/s40164-017-0089-y. eCollection 2017.
5
Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11.
6
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
Lancet Oncol. 2016 Jul;17(7):984-993. doi: 10.1016/S1470-2045(16)30146-2. Epub 2016 Jun 6.
7
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Lancet Oncol. 2016 May;17(5):642-50. doi: 10.1016/S1470-2045(16)00077-2. Epub 2016 Apr 11.
8
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309.
9
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.
J Thorac Oncol. 2015 Oct;10(10):1451-7. doi: 10.1097/JTO.0000000000000625.
10
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):E748-57. doi: 10.1073/pnas.1320956111. Epub 2014 Feb 3.
Zotero 插件